[dleavitt]

The article didn't focus too much on solutions, though a couple of things were mentioned: 1. Reducing patent protection 2. Price controls (?)

So let's assume we want these companies to reduce their profit margins (and instead lower drug prices or spend more on R&D.) What _are_ the best policy tools to incentivize this while minimizing market distortions, etc?

[ajmurmann]

Wouldn't both reduced patent protections and price controls reduce incentive to invest in R&D and for private investors likewise reduce incentive to invest in pharma that invests in R&D?